Bristol Myers Squibb is defending its clinical pipeline after a patient death in an autoimmune trial, reassuring investors over its broader immunology strategy.

Bristol Myers Squibb has raised its annual financial outlook following stronger-than-expected quarterly revenue, driven by robust uptake in its growth portfolio.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

Automakers and logistics operators confront shifting consumer demand, capital expenditure hurdles, and freight market stabilization across global markets.

Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.

Dropbox is trimming roughly 6% of its global workforce as the cloud storage pioneer recalibrates operating expenses toward core profitability and artificial intelligence.

Biogen swung to a quarterly net loss even as top-line revenue advanced, driven by new product launches and heavy pipeline realignment expenses.

Video game publishers and investors are tightening balance sheets, setting aside high-overhead experiments to prioritize capital efficiency and proven franchises.

Institutional investors are closely analyzing political strategies aimed at swing voters, assessing the long-term ramifications for fiscal policy, corporate taxation, and regulatory agendas.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.

Biopharma executives are dismantling traditional corporate silos to accelerate drug development, streamline clinical trials, and maximize capital efficiency.

As artificial intelligence startups burn billions on compute infrastructure, unconventional adjusted metrics risk masking severe cash burn for private tech valuations.